We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
MedDay Pharmaceuticals has announced new top-line data showing that its experimental drug MD1003 missed the primary and secondary endpoints of the Phase III SPI2 trial.